Prognostic significance of ezrin expression in liposarcoma

Korean Journal of Pathology

Volumn 42, Issue 5, 2008, Pages 270-276

  Lee, Jae Seok ^a   Jin, Min Sun ^a   Lee, Jung Eun ^b   Kim, Min Suk ^a   Jeon, Dae Geun ^a   Koh, Jae Soo ^a  

^a Korea Cancer Center Hospital   (South Korea)

^b Korea Institute of Radiation and Medical Science   (South Korea)

Author keywords

Ezrin; Liposarcoma; Metastasis

Indexed keywords

EID: 59849121671     PISSN: 17381843     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Weiss SW, Goldblum JR. Enzinger and Weiss's soft tissue tumors. 4th ed. St Louis: Mosby, 2001.
2. Gebhard S, Coindre JM, Michels JJ, et al. Pleomorphic liposarcoma: clinicopathologic, immunohistochemical, and follow-up analysis of 63 cases. Am J Surg Pathol 2002; 26: 601-16.
3. Pearlstone DB, Pisters PW, Bold RJ, et al. Patterns of recurrence in extremity liposarcoma: implications for staging and follow-up. Cancer 1999; 85: 85-92.
4. Greene FL, Page DL, Flemming FD. American Joint Committee on Cancer: cancer staging manual. 6th ed. New York: Springer, 2002.
5. Smith TA, Easley KA, Goldblum JR. Myxoid/round cell liposarcoma of the extremities: a clinicopathologic study of 29 cases with particular attention to extent of round cell liposarcoma. Am J Surg Pathol 1996; 20: 171-80.
6. Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 2004; 10: 182-6.
7. Hunter KW. Ezrin, a key component in tumor metastasis. Trends Mol Med 2004; 10: 201-4.
8. Weng WH, Ahlen J, Astrom K, Lui WO, Larsson C. Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas. Clin Cancer Res 2005; 11: 6198-204.
9. Spillane AJ, Fisher C, Thomas JM. Myxoid liposarcoma: the frequency and the natural history of nonpulmonary soft tissue metastases. Ann Surg Oncol 1999; 6: 389-94.
10. Chang HR, Gaynor J, Tan C, Hajdu SI, Brennan MF. Multifactorial analysis of survival in primary extremity liposarcoma. World J Surg 1990; 14: 610-8.
11. Eilber FC, Eilber FR, Eckardt J, et al. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Ann Surg 2004; 240: 686-95.
12. Zagars GK, Goswitz MS, Pollack A. Liposarcoma: outcome and prognostic factors following conservation surgery and radiation therapy. Int J Radiat Oncol Biol Phys 1996; 36: 311-9.
13. Jones RL, Fisher C, Al-Muderis O, Judson IR. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer 2005; 41: 2853-60.
14. Wan X, Mendoza A, Khanna C, Helman LJ. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 2005; 65: 2406-11.